Olier I, et al. - Using the British Cardiovascular Interventional Society national database, researchers assessed the comparative outcomes of two newer drugs (prasugrel and ticagrelor) in the context of primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). In a cohort of patients undergoing primary PCI for STEMI in the UK, prasugrel was observed to be associated with a lower 30-day and 1-year mortality than clopidogrel and ticagrelor.